Epoetin beta clinical trials
How each study uses epoetin beta is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2007 (6)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2000 | 1 |
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 4 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 6 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 20 · Other 20
Hoffmann-La Roche (17) · Groupe Francophone des Myelodysplasies (3) · Centre Hospitalier Universitaire, Amiens (2) · Seoul National University Bundang Hospital (2) · Imperial College Healthcare NHS Trust (1) · Imperial College London (1) · University Hospital, Angers (1) · JW Pharmaceutical (1)
Often tested with
Tested in the same studies.
Iron sucrose (3) · Lenalidomide (1) · Mycophenolic Acid (1) · Prednisone (1) · Cisplatin (1) · Epoetin Alfa (1)
Related medicines
As reviewed, each with the page that says it.
- A recombinant medicine of Erythropoietin source
Studies
Open first, then newest update. How each study uses epoetin beta is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 40
- Correction of Anaemia and Progression of Renal Failure on Transplanted PatientsCompletedPhase 4Centre Hospitalier Universitaire, AmiensNCT00396435Written as NeorecormonHow we know
- Epoetin Beta in Patients Undergoing Chemotherapy for Solid TumorsTerminatedNot applicableInstitut du Cancer de Montpellier - Val d'AurelleNCT00875004Written as epoetin betaHow we know
- Treatment Response in Dialysis AnaemiaCompletedPhase 4Imperial College Healthcare NHS TrustNCT02707757Written as Erythopoietin stimulating agentHow we know
- A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)CompletedPhase 4Hoffmann-La RocheNCT02145026Written as Epoetin betaHow we know
- Predictors of Response to Iron and Erythropoietin Stimulating AgentsCompletedPhase 4Imperial College LondonNCT03658876Written as Epoetin BetaHow we know
- A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing ChemotherapyCompletedPhase 2Hoffmann-La RocheNCT02761642Written as Epoetin BetaHow we know
- A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid MalignanciesCompletedPhase 4Hoffmann-La RocheNCT00776425Written as Epoetin betaHow we know
- A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With ChemotherapyCompletedPhase 3Hoffmann-La RocheNCT02767765Written as r-HuEPOHow we know
- Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.CompletedPhase 2Groupe Francophone des MyelodysplasiesNCT01718379Written as Epoetin betaHow we know
- A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic MalignanciesCompletedPhase 4Hoffmann-La RocheNCT02564094Written as Epoetin betaHow we know
- COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.CompletedPhase 4Hoffmann-La RocheNCT00377481Written as epoetin beta [NeoRecormon]How we know
- A Study of Epoetin Beta (NeoRecormon) in Participants With Solid TumorsCompletedPhase 4Hoffmann-La RocheNCT02554942Written as Epoetin betaHow we know
- A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal AnemiaCompletedPhase 4Hoffmann-La RocheNCT02569515Written as Epoetin BetaHow we know
- A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin BTerminatedPhase 4Hoffmann-La RocheNCT02608060Written as Epoetin BetaHow we know
- A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid MalignancyTerminatedPhase 4Hoffmann-La RocheNCT02624141Written as Epoetin BetaHow we know
- A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.CompletedPhase 2Hoffmann-La RocheNCT00551291Written as Erythropoietin BetaHow we know
- A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on DialysisCompletedPhase 3Hoffmann-La RocheNCT02827266Written as Epoetin betaHow we know
- A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal AnemiaCompletedPhase 3Hoffmann-La RocheNCT00321919Written as epoetin beta [NeoRecormon]How we know
- Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney TransplantCompletedPhase 3Centre Hospitalier Universitaire, AmiensNCT00815867Written as epoetin beta (NeoRecormon ®)How we know
- (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic NephropathyCompletedPhase 3Hoffmann-La RocheNCT00354341Written as Epoetin betaHow we know
See all 40 studies that test epoetin beta →
Given beside what is tested · 5 — epoetin beta is usual care or a partner of the new treatment
- Paricalcitol Improves Anemia of InflammationTerminatedPhase 4Hospital Son EspasesNCT02876211Written as Epoetin betaHow we know
- A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)CompletedPhase 4Hoffmann-La RocheNCT00773513Written as Epoetin BetaHow we know
- A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.CompletedPhase 4Hoffmann-La RocheNCT00560274Written as epoetin beta [NeoRecormon]How we know
- Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)CompletedPhase 4University Hospital, Basel, SwitzerlandNCT01306409Written as cera, darbepoetin, epoetin-betaHow we know
- Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected PatientsStatus unknownPhase 4Hospital Carlos III, MadridNCT00526448Written as epoetin betaHow we know
As the comparator · 6 — what is tested is compared with epoetin beta
- A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.CompletedPhase 3Hoffmann-La RocheNCT00717821Written as Epoetin BetaHow we know
- Comparison Among Erythropoietin Stimulating AgentsCompletedPhase 4Hamad Medical CorporationNCT02049346Written as Epoetin alpha or beta (Epoetin group)How we know
- A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.CompletedPhase 3Hoffmann-La RocheNCT00773331Written as epoetin betaHow we know
- A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.CompletedPhase 3Hoffmann-La RocheNCT00442793Written as Epoetin betaHow we know
- A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal AnemiaCompletedPhase 3Hoffmann-La RocheNCT00090753Written as Epoetin betaHow we know
- Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)CompletedPhase 3Chugai PharmaceuticalNCT00492427Written as Epoetin betaHow we know